Dynavax Technologies Corporation (DVAX)
After hours:
| Previous Close | 11.01 |
| Open | 11.06 |
| Bid | 10.71 x 500 |
| Ask | 10.77 x 200 |
| Day's Range | 10.62 - 11.10 |
| 52 Week Range | 10.48 - 15.15 |
| Volume | |
| Avg. Volume | 2,039,975 |
| Market Cap | 1.404B |
| Beta (5Y Monthly) | 1.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2024.
- PR Newswire
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close.
- PR Newswire
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at TD Cowen's 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET.
